WO2008147864A3 - Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions - Google Patents
Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions Download PDFInfo
- Publication number
- WO2008147864A3 WO2008147864A3 PCT/US2008/064498 US2008064498W WO2008147864A3 WO 2008147864 A3 WO2008147864 A3 WO 2008147864A3 US 2008064498 W US2008064498 W US 2008064498W WO 2008147864 A3 WO2008147864 A3 WO 2008147864A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- conditions
- sodium channel
- mediated diseases
- methods
- piperazine compounds
- Prior art date
Links
- 108010052164 Sodium Channels Proteins 0.000 title abstract 2
- 102000018674 Sodium Channels Human genes 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 150000004885 piperazines Chemical class 0.000 title abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- -1 as stereoisomers Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention is directed to piperazine compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93958607P | 2007-05-22 | 2007-05-22 | |
US60/939,586 | 2007-05-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008147864A2 WO2008147864A2 (en) | 2008-12-04 |
WO2008147864A3 true WO2008147864A3 (en) | 2009-07-09 |
Family
ID=40075732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/064498 WO2008147864A2 (en) | 2007-05-22 | 2008-05-22 | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008147864A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104398516A (en) * | 2009-02-20 | 2015-03-11 | 阿斯利康(瑞典)有限公司 | Cyclopropyl amide derivatives targeting the histamine h3 receptor |
CN110204511B (en) * | 2019-06-27 | 2023-04-11 | 南京神奇科技开发有限公司 | Thymol amino alcohol and preparation method and application thereof |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE478044T1 (en) | 2005-09-16 | 2010-09-15 | Arrow Therapeutics Ltd | BIPHENYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS C |
PL2142529T3 (en) | 2007-04-27 | 2014-06-30 | Purdue Pharma Lp | Trpv1 antagonists and uses thereof |
TWI432422B (en) | 2007-08-22 | 2014-04-01 | Astrazeneca Ab | Cyclopropyl guanamine derivative |
US8673920B2 (en) | 2009-05-06 | 2014-03-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
SG182732A1 (en) | 2010-02-18 | 2012-08-30 | Astrazeneca Ab | New crystalline form of a cyclopropyl benzamide derivative |
US8999974B2 (en) | 2010-08-09 | 2015-04-07 | Raqualia Pharma Inc. | Acyl piperazine derivatives as TTX-S blockers |
WO2012058116A1 (en) | 2010-10-27 | 2012-05-03 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EP2632464B1 (en) | 2010-10-29 | 2015-04-29 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
MX354015B (en) | 2011-06-22 | 2018-02-08 | Shionogi & Co | TRPV1 ANTAGONISTS THAT INCLUDE SUBSTITUTES DIHIDROXI AND ITS USES. |
EP2729149A4 (en) * | 2011-07-06 | 2015-01-07 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
RU2014110401A (en) | 2011-08-19 | 2015-09-27 | Мерк Шарп И Доум Корп. | KIDNEY EXTERNAL KIDNEY KIDNEY CHANNEL INHIBITORS |
US9527830B2 (en) | 2011-09-16 | 2016-12-27 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EP2771004B1 (en) | 2011-10-25 | 2016-05-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US8999990B2 (en) | 2011-10-25 | 2015-04-07 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9139585B2 (en) | 2011-10-31 | 2015-09-22 | Merck Sharp & Dohme Corp. | Inhibitors of the Renal Outer Medullary Potassium channel |
EP2773206B1 (en) | 2011-10-31 | 2018-02-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9493474B2 (en) | 2011-10-31 | 2016-11-15 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9206199B2 (en) | 2011-12-16 | 2015-12-08 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
AR092031A1 (en) | 2012-07-26 | 2015-03-18 | Merck Sharp & Dohme | INHIBITORS OF THE EXTERNAL RENAL MEDULAR POTASSIUM CHANNEL |
WO2014085210A1 (en) | 2012-11-29 | 2014-06-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EP2934533B1 (en) | 2012-12-19 | 2017-11-15 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EP2956142B1 (en) | 2013-02-18 | 2017-09-20 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9765074B2 (en) | 2013-03-15 | 2017-09-19 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9751881B2 (en) | 2013-07-31 | 2017-09-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2016127358A1 (en) | 2015-02-12 | 2016-08-18 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
KR102093409B1 (en) * | 2019-10-23 | 2020-03-25 | 고려대학교 산학협력단 | Anti-fungal Composition Comprising Carbazole Compound |
CN111662288B (en) * | 2020-06-23 | 2022-06-14 | 徐州医科大学 | A small molecule compound that inhibits the activity of AKT and STAT3 and its application |
US20240300934A1 (en) * | 2021-07-07 | 2024-09-12 | Trustees Of Tufts College | Compounds for modulating mycobacterium tuberculosis response |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5354747A (en) * | 1993-06-16 | 1994-10-11 | G. D. Searle & Co. | 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use |
WO1996037489A1 (en) * | 1995-05-25 | 1996-11-28 | Fujisawa Pharmaceutical Co., Ltd. | 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists |
WO1997043259A1 (en) * | 1996-05-10 | 1997-11-20 | Monash University | Arylalkylpiperazine compounds as antioxidants |
US20040034019A1 (en) * | 2002-08-08 | 2004-02-19 | Ronald Tomlinson | Piperazine and piperidine derivatives |
WO2004032933A1 (en) * | 2002-10-11 | 2004-04-22 | Kowa Co., Ltd. | Method for treatment of cancer |
US20050227999A1 (en) * | 2004-04-09 | 2005-10-13 | Neuromed Technologies Inc. | Diarylamine derivatives as calcium channel blockers |
WO2006028904A1 (en) * | 2004-09-02 | 2006-03-16 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
WO2007109324A2 (en) * | 2006-03-21 | 2007-09-27 | Xenon Pharmaceuticals, Inc. | Potent and selective nav 1.7 sodium channel blockers |
-
2008
- 2008-05-22 WO PCT/US2008/064498 patent/WO2008147864A2/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5354747A (en) * | 1993-06-16 | 1994-10-11 | G. D. Searle & Co. | 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use |
WO1996037489A1 (en) * | 1995-05-25 | 1996-11-28 | Fujisawa Pharmaceutical Co., Ltd. | 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists |
WO1997043259A1 (en) * | 1996-05-10 | 1997-11-20 | Monash University | Arylalkylpiperazine compounds as antioxidants |
US20040034019A1 (en) * | 2002-08-08 | 2004-02-19 | Ronald Tomlinson | Piperazine and piperidine derivatives |
WO2004032933A1 (en) * | 2002-10-11 | 2004-04-22 | Kowa Co., Ltd. | Method for treatment of cancer |
US20050227999A1 (en) * | 2004-04-09 | 2005-10-13 | Neuromed Technologies Inc. | Diarylamine derivatives as calcium channel blockers |
WO2006028904A1 (en) * | 2004-09-02 | 2006-03-16 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
WO2007109324A2 (en) * | 2006-03-21 | 2007-09-27 | Xenon Pharmaceuticals, Inc. | Potent and selective nav 1.7 sodium channel blockers |
Non-Patent Citations (2)
Title |
---|
CARCELLER E ET AL: "(Pyridylcyanomethyl)piperazines as Orally Active PAF Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON.; US, vol. 35, no. 22, 30 October 1992 (1992-10-30), pages 4118 - 4134, XP002008877, ISSN: 0022-2623 * |
CLARE J J ET AL: "Voltage-Gated Sodium Channels as Therapeutic Targets", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 5, no. 11, 1 November 2000 (2000-11-01), pages 506 - 520, XP002985023, ISSN: 1359-6446 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104398516A (en) * | 2009-02-20 | 2015-03-11 | 阿斯利康(瑞典)有限公司 | Cyclopropyl amide derivatives targeting the histamine h3 receptor |
CN110204511B (en) * | 2019-06-27 | 2023-04-11 | 南京神奇科技开发有限公司 | Thymol amino alcohol and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2008147864A2 (en) | 2008-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008147864A3 (en) | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions | |
WO2010045251A3 (en) | Spiro-oxindole compounds and their use as therapeutic agents | |
MX2009008338A (en) | Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions. | |
WO2008094909A3 (en) | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions | |
WO2008121861A3 (en) | Pyrazole and pyrrole compounds useful in treating iron disorders | |
WO2010132352A3 (en) | Spiro compounds and their use as therapeutic agents | |
MX2009012168A (en) | Pyrrolopyridine derivatives and their use as bace inhibitors. | |
TW200724543A (en) | Heterocyclic compounds and their uses as therapeutic agents | |
GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
TW200734311A (en) | New compounds | |
WO2008149382A8 (en) | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application | |
WO2008115999A8 (en) | Biaryl and biheteroaryl compounds useful in treating iron disorders | |
WO2008151288A3 (en) | Aromatic and heteroaromatic compounds useful in treating iron disorders | |
WO2006113864A3 (en) | Oxindole compounds and their uses as therapeutic agents | |
MY167135A (en) | Fused heterocyclic derivatives and methods of use | |
TN2012000171A1 (en) | Synthetic methods for spiro-oxindole compounds | |
GEP20084439B (en) | Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof | |
MY157017A (en) | Sulfonamide derivatives | |
WO2009047798A3 (en) | Acetamide derivatives as glucokinase activators, their process and medicinal applications | |
TW200736233A (en) | Cyclohexyl piperazinyl methanone derivatives | |
UA85471C2 (en) | Use of oxycodone for treating visceral pain | |
MX2009003874A (en) | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents. | |
SI2054418T1 (en) | Dihydrothieno pyrimidines as akt protein kinase inhibitors | |
WO2011028044A3 (en) | Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same | |
WO2011028043A3 (en) | Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08769604 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08769604 Country of ref document: EP Kind code of ref document: A2 |